These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

549 related articles for article (PubMed ID: 31059311)

  • 1. Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma.
    Christensen E; Birkenkamp-Demtröder K; Sethi H; Shchegrova S; Salari R; Nordentoft I; Wu HT; Knudsen M; Lamy P; Lindskrog SV; Taber A; Balcioglu M; Vang S; Assaf Z; Sharma S; Tin AS; Srinivasan R; Hafez D; Reinert T; Navarro S; Olson A; Ram R; Dashner S; Rabinowitz M; Billings P; Sigurjonsson S; Andersen CL; Swenerton R; Aleshin A; Zimmermann B; Agerbæk M; Lin CJ; Jensen JB; Dyrskjøt L
    J Clin Oncol; 2019 Jun; 37(18):1547-1557. PubMed ID: 31059311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis.
    Birkenkamp-Demtröder K; Christensen E; Nordentoft I; Knudsen M; Taber A; Høyer S; Lamy P; Agerbæk M; Jensen JB; Dyrskjøt L
    Eur Urol; 2018 Apr; 73(4):535-540. PubMed ID: 28958829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating Tumor DNA Analysis in Advanced Urothelial Carcinoma: Insights from Biological Analysis and Extended Clinical Follow-up.
    Lindskrog SV; Birkenkamp-Demtröder K; Nordentoft I; Laliotis G; Lamy P; Christensen E; Renner D; Andreasen TG; Lange N; Sharma S; ElNaggar AC; Liu MC; Sethi H; Aleshin A; Agerbæk M; Jensen JB; Dyrskjøt L
    Clin Cancer Res; 2023 Dec; 29(23):4797-4807. PubMed ID: 37782315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating tumor DNA as a Predictive and Prognostic Biomarker in the Perioperative Treatment of Muscle-invasive Bladder Cancer: A Systematic Review.
    Crupi E; de Padua TC; Marandino L; Raggi D; Dyrskjøt L; Spiess PE; Sonpavde GP; Kamat AM; Necchi A
    Eur Urol Oncol; 2024 Feb; 7(1):44-52. PubMed ID: 37330413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole-genome Mutational Analysis for Tumor-informed Detection of Circulating Tumor DNA in Patients with Urothelial Carcinoma.
    Nordentoft I; Lindskrog SV; Birkenkamp-Demtröder K; Gonzalez S; Kuzman M; Levatic J; Glavas D; Ptashkin R; Smadbeck J; Afterman D; Lauterman T; Cohen Y; Donenhirsh Z; Tavassoly I; Alon U; Frydendahl A; Rasmussen MH; Andersen CL; Lamy P; Knudsen M; Polak P; Zviran A; Oklander B; Agerbæk M; Jensen JB; Dyrskjøt L
    Eur Urol; 2024 May; ():. PubMed ID: 38811314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.
    Watanabe F; Suzuki K; Tamaki S; Abe I; Endo Y; Takayama Y; Ishikawa H; Kakizawa N; Saito M; Futsuhara K; Noda H; Konishi F; Rikiyama T
    PLoS One; 2019; 14(12):e0227366. PubMed ID: 31891652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postoperative recurrence detection using individualized circulating tumor DNA in upper tract urothelial carcinoma.
    Tamura D; Abe M; Hiraki H; Sasaki N; Yashima-Abo A; Ikarashi D; Kato R; Kato Y; Maekawa S; Kanehira M; Takata R; Maejima K; Sasagawa S; Fujita M; Suzuki Y; Nakagawa H; Iwaya T; Nishizuka SS; Obara W
    Cancer Sci; 2024 Feb; 115(2):529-539. PubMed ID: 38083992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perioperative circulating tumor DNA enables the identification of patients with poor prognosis in upper tract urothelial carcinoma.
    Nakano K; Koh Y; Yamamichi G; Yumiba S; Tomiyama E; Matsushita M; Hayashi Y; Wang C; Ishizuya Y; Yamamoto Y; Kato T; Hatano K; Kawashima A; Ujike T; Fujita K; Kiyotani K; Katayama K; Yamaguchi R; Imoto S; Imamura R; Nonomura N; Uemura M
    Cancer Sci; 2022 May; 113(5):1830-1842. PubMed ID: 35293110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using Tumor-Informed Circulating Tumor DNA (ctDNA)-Based Testing for Patients with Anal Squamous Cell Carcinoma.
    Azzi G; Tavallai M; Aushev VN; Koyen Malashevich A; Botta GP; Tejani MA; Hanna D; Krinshpun S; Malhotra M; Jurdi A; Aleshin A; Kasi PM
    Oncologist; 2023 Mar; 28(3):220-229. PubMed ID: 36562592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences.
    Henriksen TV; Tarazona N; Frydendahl A; Reinert T; Gimeno-Valiente F; Carbonell-Asins JA; Sharma S; Renner D; Hafez D; Roda D; Huerta M; Roselló S; Madsen AH; Løve US; Andersen PV; Thorlacius-Ussing O; Iversen LH; Gotschalck KA; Sethi H; Aleshin A; Cervantes A; Andersen CL
    Clin Cancer Res; 2022 Feb; 28(3):507-517. PubMed ID: 34625408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study.
    Pécuchet N; Zonta E; Didelot A; Combe P; Thibault C; Gibault L; Lours C; Rozenholc Y; Taly V; Laurent-Puig P; Blons H; Fabre E
    PLoS Med; 2016 Dec; 13(12):e1002199. PubMed ID: 28027313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Implications of Monitoring Circulating Tumor DNA in Patients with Colorectal Cancer.
    Schøler LV; Reinert T; Ørntoft MW; Kassentoft CG; Árnadóttir SS; Vang S; Nordentoft I; Knudsen M; Lamy P; Andreasen D; Mortensen FV; Knudsen AR; Stribolt K; Sivesgaard K; Mouritzen P; Nielsen HJ; Laurberg S; Ørntoft TF; Andersen CL
    Clin Cancer Res; 2017 Sep; 23(18):5437-5445. PubMed ID: 28600478
    [No Abstract]   [Full Text] [Related]  

  • 13. Resectable lung lesions malignancy assessment and cancer detection by ultra-deep sequencing of targeted gene mutations in plasma cell-free DNA.
    Peng M; Xie Y; Li X; Qian Y; Tu X; Yao X; Cheng F; Xu F; Kong D; He B; Liu C; Cao F; Yang H; Yu F; Xu C; Tian G
    J Med Genet; 2019 Oct; 56(10):647-653. PubMed ID: 30981987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer.
    Reinert T; Henriksen TV; Christensen E; Sharma S; Salari R; Sethi H; Knudsen M; Nordentoft I; Wu HT; Tin AS; Heilskov Rasmussen M; Vang S; Shchegrova S; Frydendahl Boll Johansen A; Srinivasan R; Assaf Z; Balcioglu M; Olson A; Dashner S; Hafez D; Navarro S; Goel S; Rabinowitz M; Billings P; Sigurjonsson S; Dyrskjøt L; Swenerton R; Aleshin A; Laurberg S; Husted Madsen A; Kannerup AS; Stribolt K; Palmelund Krag S; Iversen LH; Gotschalck Sunesen K; Lin CJ; Zimmermann BG; Lindbjerg Andersen C
    JAMA Oncol; 2019 Aug; 5(8):1124-1131. PubMed ID: 31070691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma-Derived Cell-Free DNA as a Biomarker for Early Detection, Prognostication, and Personalized Treatment of Urothelial Carcinoma.
    Bhalla S; Passarelli R; Biswas A; De S; Ghodoussipour S
    J Clin Med; 2024 Apr; 13(7):. PubMed ID: 38610824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-Agnostic Circulating Tumor DNA Testing for Monitoring Muscle-Invasive Bladder Cancer.
    Carrasco R; Ingelmo-Torres M; Trullas R; Roldán FL; Rodríguez-Carunchio L; Juez L; Sureda J; Alcaraz A; Mengual L; Izquierdo L
    Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38068899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumor DNA predicts neoadjuvant immunotherapy efficacy and recurrence-free survival in surgical non-small cell lung cancer patients.
    Yue D; Liu W; Chen C; Zhang T; Ma Y; Cui L; Gu Y; Bei T; Zhao X; Zhang B; Bai Y; Romero A; Xu-Welliver M; Wang C; Zhang Z; Zhang B
    Transl Lung Cancer Res; 2022 Feb; 11(2):263-276. PubMed ID: 35280315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-specific targeted analysis of circulating tumour DNA in plasma is feasible and may be a potential biomarker in UTUC.
    Mu N; Jylhä C; Axelsson T; Sydén F; Brehmer M; Tham E
    World J Urol; 2023 Dec; 41(12):3421-3427. PubMed ID: 37721600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients.
    Cheng H; Liu C; Jiang J; Luo G; Lu Y; Jin K; Guo M; Zhang Z; Xu J; Liu L; Ni Q; Yu X
    Int J Cancer; 2017 May; 140(10):2344-2350. PubMed ID: 28205231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Review of Circulating Tumor DNA in the Diagnosis and Monitoring of Esophageal Cancer.
    Min J; Zhou H; Jiang S; Yu H
    Med Sci Monit; 2022 Feb; 28():e934106. PubMed ID: 35210388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.